+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Benign Prostatic Hyperplasia Market: By Diagnosis Test, Digital Rectal Examination and Others; By Treatment Procedures; By Geography - Forecast 2018 to 2023

  • ID: 4532405
  • Report
  • January 2018
  • Region: Global
  • 161 Pages
  • IndustryARC
Benign Prostatic Hyperplasia (BPH) refers to a physical condition in men, which leads to the proliferation of prostatic stromal cells in a non-cancerous way that results in an enlarged prostate gland. Benign prostatic hyperplasia (BPH) is also referred as benign prostatic hypertrophy or benign prostatic obstruction. Owing to the factors such as lack of physical exercise, erectile dysfunction, medical conditions such as obesity, heart and circulatory disease and type2 diabetes are propelling the growth of the market. Moreover, family history of benign prostatic
Hyperplasia and men aged 40 years and above are more prone to the BPH disorder.

The Global Benign Prostatic Hyperplasia (BPH) are classified on the basis of various parameters. On the basis of symptoms the market is classified into Difficulty in Bladder Emptying, Frequent Urination, Straining, Post Urination Dribbling or Weak Stream and Others. On the basis of diagnosis the market is segmented into Prostate-Specific Antigen (PSA) Test, Digital Rectal Examination (DRE) and Others. Based on treatment procedures the market is segregated into Medical Therapies, Surgical Therapies, Minimally Invasive Therapies, Laser Surgical Therapies, Needle Ablation and Others.


In terms of Geography, the global Benign Prostatic Hyperplasia (BPH) market is classified into North America, Europe, APAC and Row. North America is expected to be the major player in the Benign Prostatic Hyperplasia (BPH) market followed by Asia Pacific. Asia-Pacific is projected to witness the highest growth during the forecast period having the emerging countries such as China, India and Japan in this region.
Key market players in the global Benign Prostatic Hyperplasia (BPH) market include companies such as Astellas Pharma (Japan), Eli Lilly (U.S.), GlaxoSmithKline (U.K), Sanofi (France) and few others.
Note: Product cover images may vary from those shown

1. Global Benign Prostatic Hyperplasia (BPH) - Market Overview2. Global Benign Prostatic Hyperplasia (BPH) - Executive Summary
3. Global Benign Prostatic Hyperplasia (BPH) - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End user profiling
3.5. Top 5 Financials Analysis
4. Global Benign Prostatic Hyperplasia (BPH) - Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Global Benign Prostatic Hyperplasia (BPH) - Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
6. Global Benign Prostatic Hyperplasia (BPH) Market - By Diagnosis
6.1. Prostate-Specific Antigen (PSA) Test
6.2. Digital Rectal Examination (DRE)
6.3. Others
7. Global Benign Prostatic Hyperplasia (BPH) Market - By Treatment Procedures
7.1. Medical Therapies
7.1.1. Alpha-Blockers Alfuzosin Doxazosin Tamsulosin Terazosin Others
7.1.2. 5- Alpha-reductase inhibitors (5-ARIs) Dutasteride Finasteride
7.1.3. Combination Therapy Alpha Blocker and 5-Alpha-Reductase Inhibitor Alpha Blocker and Anticholinergics
7.1.4. Anticholinergic Agents
7.2. Surgical Therapies
7.2.1. Open Prostatectomy
7.2.2. Photoselective Vaporization of The Prostate (PVP)
7.2.3. Transurethral Incision of The Prostate (TUIP)
7.2.4. Transurethral Vaporization of The Prostate (TUVP)
7.2.5. Transurethral Resection of the Prostate (TURP)
7.3. Minimally Invasive Therapies
7.3.1. Transurethral needle ablation (TUNA)
7.3.2. Transurethral microwave thermotherapy (TUMT)
7.4. Laser Surgical Therapies
7.4.1. Holmium Laser Enucleation of the Prostate (HoLEP)
7.4.2. Holmium Laser Ablation of the Prostate (HoLVP)
7.4.3. Holmium laser resection of the prostate (HoLRP)
7.5. Needle Ablation
7.6. Others
8. Global Benign Prostatic Hyperplasia (BPH) Market - By Geography
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. Spain
8.2.4. Italy
8.2.5. U.K.
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Rest of APAC
8.4. RoW
8.4.1. South America
8.4.2. Middle East
8.4.3. Africa
9. Global Benign Prostatic Hyperplasia (BPH) Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Astellas Pharma
10.2. Eli Lilly
10.3. GlaxoSmithKline
10.4. Sanofi
10.5. ADC Therapeutics
10.6. Advaxis
10.7. ANI Pharmaceuticals
10.8. Bayer HealthCare
10.9. BHR Pharma
10.10. Bristol-Myers Squibb
10.11. Boehringer Ingelheim
10.12. Novartis
10.13. Teva Pharmaceutical Industries
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown